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Assessment of in vitro susceptibility is a fundamental component of antimalarial surveillance studies, but wide variations in the
measurement of parasite growth and the calculation of inhibitory constants make comparisons of data from different laborato-
ries difficult. Here we describe aWeb-based, high-throughput in vitro analysis and reporting tool (IVART) generating inhibitory
constants for large data sets. Fourteen primary data sets examining laboratory-determined susceptibility to artemisinin deriva-
tives and artemisinin combination therapy partner drugs were collated from 11 laboratories. Drug concentrations associated
with half-maximal inhibition of growth (IC50s) were determined by a modified sigmoid Emax model-fitting algorithm, allowing
standardized analysis of 7,350 concentration-inhibition assays involving 1,592 isolates. Examination of concentration-inhibition
data revealed evidence of apparent paradoxical growth at high concentrations of nonartemisinin drugs, supporting amendment
of the method for calculating the maximal drug effect in each assay. Criteria for defining more-reliable IC50s based on estimated
confidence intervals and growth ratios improved correlation coefficients for the drug pairs mefloquine-quinine and chloro-
quine-desethylamodiaquine in 9 of 11 and 8 of 8 data sets, respectively. Further analysis showed that maximal drug inhibition
was higher for artemisinins than for other drugs, particularly in ELISA (enzyme-linked immunosorbent assay)-based assays, a
finding consistent with the earlier onset of action of these drugs in the parasite life cycle. This is the first high-throughput analyt-
ical approach to apply consistent constraints and reliability criteria to large, diverse antimalarial susceptibility data sets. The
data also illustrate the distinct biological properties of artemisinins and underline the need to apply more sensitive approaches
to assessing in vitro susceptibility to these drugs.
The mission of the WorldWide Antimalarial Resistance Net-work (WWARN) is to enhance the quality, quantity, and geo-
graphic extent of drug susceptibility data available to the malaria
control community via a global data repository. Laboratory-based
assessment of parasites in culture (“in vitro”) enables measure-
ment of the intrinsic drug susceptibility of Plasmodium falciparum
without the confounding effects of host pharmacokinetics, immu-
nity, and genetics (1). Parasites with reduced antimalarial suscep-
tibilities can be established in continuous culture, allowing the
investigation of molecular mechanisms of resistance as well as the
assessment of susceptibility to other antimalarial agents (2). In an
era when artemisinin combination therapies (ACTs) are recom-
mended treatment for falciparum malaria worldwide, additional
considerations apply. While the use of a combination is beneficial
in therapeutic terms, resistance to either partner alone can de-
velop without an immediate reduction in clinical treatment effi-
cacy. Assessment of drug susceptibility in parasites isolated di-
rectly from patients provides an opportunity to detect resistance
to each individual drug at a relatively early stage, potentially al-
lowing appropriate action before clinically relevant drug failure
occurs (1).
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One challenge facing the in vitro field is that culture-based
assessment of parasite susceptibility has undergone a natural evo-
lution since techniques for studying chloroquine (CQ) resistance
were established more than 4 decades ago (3). The basic measure-
ment of drug susceptibility is the growth of parasites in the pres-
ence of a range of concentrations of a given drug, expressed as the
concentration of the drug needed to suppress growth to 50% of
that observed in the absence of the drug (50% inhibitory concen-
tration [IC50]). A wide variety of readout methods for assessing
parasite growth have been described (4, 5), including microscopic
assessment (6), incorporation of radiolabeled hypoxanthine (7),
production of the highly expressed P. falciparum proteins lactate
dehydrogenase (LDH) (8, 9) and histidine-rich protein 2 (HRP2)
(10), and methods involving DNA detection, such as SYBR green
fluorescence (11, 12) and flow cytometry (13). This variety of
techniques reflects practical and financial considerations that de-
fine a specific need for different assays in different settings.
All methods for phenotyping parasite responses outside the
host are to some degree surrogates for in vivo phenomena, and
although each new technique has been validated against a stan-
dard (generally hypoxanthine incorporation), differences be-
tween the methods clearly exist. Longitudinal estimates from the
same lab measured consistently over time are still informative (2,
4), but the comparison of data from different laboratories remains
a major challenge. The use of control reference clones holds the
potential to reduce this problem (2) but has rarely been achieved
over a substantive time frame.
Differences in computational methods also compromise the
comparison of results from different laboratories. Investigators
calculate inhibitory constants by a variety of means, including
algorithms within software packages and freely available tools
based on log probit (14), polynomial (10), and sigmoid inhibition
(15) models. In addition, some assays exhibiting poor growth are
misleading and should not be used as a basis for defining drug
resistance (4, 15). Standardized methods to address these issues
have been reported on occasion (16), but in general, the classifi-
cation of concentration-inhibition curves remains a time-con-
suming and potentially subjective process involving visual inspec-
tion of individual curves. The need to examine parasites isolated
directly from patients precludes repeated studies of individual
parasite isolates, further compounding these difficulties.
This work describes the development of an in vitro analysis and
reporting tool (IVART) capable of producing inhibitory constants
for large in vitro data sets in a rapid, automated manner via a Web
interface. We first sought biological evidence to better define key
elements of this tool and therefore collated a wide-ranging collec-
tion of raw data obtained in a variety of global locations, generat-
ing perhaps the most diverse data set of this type so far assembled.
Systematic examination of concentration-inhibition data from
this range of different assay readouts and drugs informed the
choice of appropriate constraints for use in curve fitting. Criteria
for defining a core subset of more-reliable assays were tested by
examining correlation coefficients for IC50s from pairs of drugs.
The data also yielded biological insights into the distinct proper-
ties of artemisinin derivatives.
MATERIALS AND METHODS
Data sets used.Primary data sets describing the growth ofP. falciparum in
culture at varying drug concentrations in individual wells of 96-well plates
were collated, allowing the comparison of data obtained using various
assay methods (microscopic assessment, radiolabeled hypoxanthine up-
take inhibition, HRP2 and Plasmodium LDH [pLDH] enzyme-linked im-
munosorbent assays [ELISA], and SYBR green). Three groups of drugs
were studied: (i) artemisinins found in ACTs, consisting of dihydroarte-
misinin (DHA), artemether (AM), and artesunate (AS); (ii) ACT partner
drugs (or active metabolites) desethylamodiaquine (DQ), lumefantrine
(LUM), mefloquine (MQ), and piperaquine (PIP); and (iii) chloroquine
(CQ) and quinine (QN), drugs that are no longer recommended for first-
line treatment of P. falciparum malaria. Data sets describing at least 40
parasite isolates were considered large enough to be included in this anal-
ysis. Fourteen data sets from 11 laboratories fulfilled these criteria (Table
1). The laboratory methodologies for many of these studies have been
described previously (17–27). The primary growth outputs from assays
TABLE 1 Data sets examined
Data
set Methoda Location
No. of
isolates Yr
Sample-to-
culture
delay (h) Artemisinin(s)b Partner(s)c
Other
drug(s)d
No. of drug-free
controls per
plate Referencee
A 3H (0) Madagascar 315 2006–2007 24–48 DHA DQ, MQ CQ, QN 3 or 12 17
B 3H (0) Travelersf 421 2010 4–48 DHA DQ, LUM, MQ CQ, QN 4–8 18
C 3H (0) French Guiana 83 2008 12–48 AM, AS, DHA DQ, LUM, MQ CQ, QN 2–4 19
D 3H (24) Thailand 42 2007 4–8 AS, DHA LUM, MQ, PIP CQ, QN 4 20
E HRP2 Colombia 57 2006–2007 0–12 DHA DQ, MQ CQ 4 21
F HRP2 Bangladesh 89 2008–2009 0–12 AS, DHA MQ CQ, QN 12 22
G HRP2 Uganda 77 2010 1–6 DHA DQ, LUM, PIP CQ, QN 12 23
H HRP2 Vietnam 48 2010–2011 2–48 DHA DQ, LUM, MQ, PIP CQ, QN 9 or 12 24
I LDH Senegal 104 2009 0–12 DHA DQ, LUM, MQ CQ, QN 9 25
J LDH Travelersf 195 2009 4–48 DHA DQ, LUM, MQ CQ, QN 4–8 18
K LDH Thailand 64 2009 4–8 DHA LUM, MQ, PIP CQ, QN 4
L SYBR Cambodia 56 2010 18–24 DHA MQ CQ, QN 8 27
M SMT Colombia 57 2006–2007 0–12 DHA DQ, MQ CQ 4 21
N SMT Ghana 94 2010 0–6 AS MQ CQ, QN 12 26
a 3H, isotopic hypoxanthine method (with the timing of addition of hypoxanthine [in hours] given in parentheses); SMT, schizont maturation test.
b DHA, dihydroartemisinin; AM, artemether; AS, artesunate.
c DQ, desethylamodiaquine; MQ, mefloquine; LUM, lumefantrine; PIP, piperaquine.
d CQ, chloroquine; QN, quinine.
e References are given for the descriptions of the methodology used at each site (not necessarily the specific data assessed).
f Samples that were obtained from returning travelers presenting to French hospitals and examined at the Centre National de Référence du Paludisme, Paris, France.
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were formatted as uniform 12-by-8 96-well plate layouts in spreadsheets
to facilitate automated processing and analysis.
Analysis of constraints for curvefitting.The levels of uninhibited and
maximally inhibited growth are key parameters in IC50 calculations. For
example, in the sigmoid Emax model, these levels represent the upper and
lower asymptotes of the concentration-inhibition curve, where Emax is
defined as the difference between these two measures of growth. The
concentration-inhibition curve can be left unconstrained at its upper and
lower ends (i.e., a 4-parameter model), particularly with large numbers of
points, but for antimalarial susceptibility studies, this is frequently not
practical, since the small number of drug concentrations used (in many
cases, only 7) can produce highly unstable estimates. The upper (baseline
growth without the drug) and lower (minimum growth) values were
therefore constrained prior to modeling. Given the variability in experi-
mental design and plate layout in the data sets examined, the upper
growth constraint for each set of drug concentration-growth data [i.e., the
baseline level of uninhibited growth, G(C0)] (see Table S1 in the supple-
mental material) was defined as the average growth in all drug-free wells
on the same plate.
Assessment of an appropriate means of determining the lower growth
constraint involved systematic examination of concentration-inhibition
data from a range of data sets. This approach took into account the bio-
logical reality that growth at the highest drug concentration, G(Cmax),
does not always correspond to the maximum drug effect because of a
paradoxical rise in the growth measured at very high drug concentrations
(Fig. 1), a phenomenon that has been noted previously (15). To explore
this issue further, we prospectively defined two measurements of growth
reduction (see Table S1 in the supplemental material) providing distinct
measures of drug efficacy: Rmax1, calculated as G(C0) G(Cmax), and the
modified measure of efficacy Rmax2, calculated as G(C0)  Gmin, where
Gmin is defined as the mean growth at the two concentrations ranked as
having the lowest mean growth in the concentration-inhibition series.
A pooled analysis of possible factors associated with the occurrence of
an apparent paradoxical increase in growth at high drug concentrations
was undertaken; this effect was considered to be present when Rmax1/
Rmax2 was0.9 (a10% rise in apparent growth over that at intermediate
drug concentrations). The roles of the drug and the assay methodology
were explored using a random-effects model (Stata, version 11.1; Stata-
Corp), with the drug and the method as fixed effects and the site as a
random effect (due to the heterogeneity between sites). Since it was sus-
pected from initial observations that this phenomenon was associated
with drugs that are relatively inactive against ring-stage parasites, DHA
was used as the reference group for the drug; it was also the most com-
monly assayed antimalarial drug in current use (1,391 assays across 13 of
the 14 data sets). Hypoxanthine incorporation was defined as the refer-
ence method.
High-throughput estimation of IC50s. Curve fitting was undertaken
using a sigmoid Emax model. In its general form, this model has four
parameters: the IC50 (the 50% effective concentration [EC50] for concen-
tration-inhibition data), a measure of the curve’s steepness at the IC50 (the
sigmoidicity factor, or gamma), and the levels of uninhibited growth and
maximally inhibited growth (see above).
Code from ICEstimator (15), based on the nls algorithm of R, which
performs successive fittings of a sigmoid Emax model to concentration-
inhibition data, was adapted within a Google Web Toolkit (GWT) Java-
based Web application to perform data transformation, standardized
analysis, and reporting of IC50s for each data set. The details of ICEstima-
tor have been described elsewhere (15). Briefly, the primary growth data
are first converted to a percentage scale, with baseline growth (no drug)
representing 100% and minimum growth (maximum drug inhibition)
representing 0%. Following this conversion, the model is constrained at
its upper and lower ends to 100% and 0%, respectively, and therefore
produces only two parameters: the IC50 and the sigmoidicity factor
(gamma). Initial values for the IC50 and gamma are determined by the
point at which growth first falls below 50% of control growth (15, 18), and
iterations are then undertaken until the limit of improvement is reached.
In case of nonfitting (because of a weak dose-response relationship or a
paucity of intermediate data points between 100% and 0%, as seen with a
very steep slope), curve fitting is attempted again with gamma fixed at 10,
based on a previous sensitivity analysis showing that gamma values
greater than 10 would not significantly alter IC50s in steep curves (15).
The sigmoid Emax model is focused primarily on determining the IC50
and the slope at this IC50, and all other points on the modeled line are
entirely determined by the IC50 and gamma. Points toward the ends of the
curve, such as the IC90 and IC95, frequently depart to some degree from
the data observed, and for this reason, these values are potentially mis-
leading and are not reported by IVART.
Assessment of criteria for defining a reliable subset of assays. It is
generally recognized that at least 30% of parasite isolates placed in short-
term culture exhibit less than optimal growth due to preexposure to drugs
or other factors contributing to reduced parasite viability (4). To detect
assays that are less reliable due to such factors, IVART was set up to
calculate the ratio of the upper and lower 95% confidence intervals of the
IC50 estimate, known as the confidence interval ratio (CIR). A threshold
CIR of3 was selected to define core assays of higher reliability for entry
into pooled analyses and association studies. The CIR parameter is not
useful in a subset of cases where modeling can be achieved only with a
fixed gamma of 10, since this becomes a 1-parameter model, with inevi-
table narrowing of confidence intervals. For this subset of fixed-gamma
assays, the growth ratio (uninhibited growth divided by maximally inhib-
ited growth) was used to define core assays of higher reliability in accor-
dance with previous recommendations (4). For each data set, the main
subset of assays in which both the IC50 and gamma were successfully
obtained was examined, and the proportion of assays with tight confi-
dence intervals (CIR, 3) was determined at four levels of the growth
ratio:2, 2 to 3, 3 to 5, and5.
The effect of applying reliability criteria was explored by examining
intraisolate Pearson correlations of IC50s for drug pairs in the whole data
set and repeating this procedure with increasingly strict criteria.
Relative efficacies of artemisinins and partner drugs. Within the 12
nonmicroscopic data sets, the growth ratio (uninhibited growth divided
by maximally inhibited growth) for each drug was compared to that for
FIG 1 Example of growth inhibition data for dihydroartemisinin (DHA) and
mefloquine (MQ), obtained by a tritiated-hypoxanthine incorporation assay
of a sample from a traveler studied at the Centre National de Référence du
Paludisme, Paris, France. In this case, a paradoxical increase in apparent
growth is observed at higher concentrations of mefloquine (MQ) but not
DHA. This phenomenon results in two distinct parameters of drug efficacy for
MQ (see Table S1 in the supplemental material).
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DHA by using the Mann-Whitney test (with Bonferroni’s correction for
the number of drugs). The relative proportions of growth inhibition by
DHA and MQ for individual parasite isolates, as illustrated in Fig. 1, were
assessed by the Wilcoxon signed-rank test.
RESULTS
Constraints for curve fitting. The 14 data sets contained 7,350
individual drug inhibition assays. Analysis of growth inhibition
characteristics revealed that 1,334 (18.1% of total) assays showed
evidence of paradoxical growth at high concentrations (a rise in
apparent growth of 10% over that at intermediate concentra-
tions). Both the nature of the drug being tested and the readout
methodology were clearly associated with this behavior. The four
ACT partners (DQ, LUM, MQ, and PIP) were associated with a
risk 2- to 3-fold greater (P, 0.001 in all cases) than that for the
reference drug, DHA, while CQ and QN showed paradoxical ef-
fects at an intermediate level (P,0.001 in both cases) (see Table
S2 in the supplemental material). The phenomenon was seen less
commonly with AS than with DHA. The assay method was also
relevant; by using hypoxanthine incorporation as the reference
group, a paradoxical increase in growth was most commonly en-
countered in assays based on LDH quantification by ELISA (odds
ratio [OR], 1.27; P, 0.007). There was also a trend toward less-
frequent occurrence in HRP2 and SYBR green assays that did not
reach statistical significance. The issue was not encountered at all
in assays assessing schizont maturation by microscopy.
These findings indicate that a paradoxical increase in growth
measured at high drug concentrations reflects biological proper-
ties of antimalarial drugs rather than being simply an experimen-
tal artifact due to equipment or human error. For this reason, it
was decided to amend the lower constraint of the sigmoid Emax
model to Gmin in order to provide a more accurate measure of
maximum inhibition, avoiding underestimation of overall drug
efficacy and spuriously low IC50s.
Reliability criteria. The default criteria for defining a subset of
more-reliable assays consisted of one main criterion, an IC50 con-
fidence interval ratio (CIR) of 3. In the subset of curves with a
fixed gamma (1,427 assays [19.4% of the total]), a growth ratio
indicating a satisfactory signal/background ratio was used to as-
sess reliability. As expected, there was a clear relationship between
the growth ratio and the CIR in the 80.6% of assays where gamma
was derived by modeling (i.e., 2-parameter models) (see Fig. S1 in
the supplemental material). Growth ratios of 3 to 5 and5 were
associated with very high levels of assays with tight confidence
interval ratios (across the 12 nonmicroscopic data sets, the median
proportions with CIRs of3 were 91.3% for a growth ratio of 3 to
5 and 95.3% for a growth ratio of5). In contrast, a growth ratio
of 2 was associated with relatively high proportions (median,
33.9%) of assays with uncertain IC50 estimates (CIR, 3). A
growth ratio of 2 to 3 was generally associated with high levels of
assays with tight confidence intervals (median proportion,
86.8%), but there did appear to be greater potential for less-reli-
able IC50 estimates to be accepted at this growth ratio level in
hypoxanthine incorporation assays (see Fig. S1 in the supplemen-
tal material, data sets A and C).
The effect of applying reliability criteria was assessed by calcu-
lating the correlation between IC50s for drug pairs within each
data set, since it was predicted that application of increasingly
strict criteria might improve correlation coefficients. MQ-QN and
CQ-DQ provided the most powerful test cases given the number
of data sets assessing each drug pair (11 and 8, respectively) and
the strong, consistently documented associations between IC50s
for these drug pairs in field studies (20, 28–33). Exclusion of assays
with CIRs of3 and growth ratios of2 (for assays with a fixed
gamma) led to stronger correlations in 9/11 data sets for MQ-QN
and in all 8 data sets for CQ-DQ (Fig. 2; see also Table S3 in the
supplemental material). Statistical significance was generally
maintained or strengthened in the more-reliable subset despite
the reduction in sample size.
Increasingly strict classification of the fixed-gamma subset of
assays, involving the exclusion of additional assays with growth
ratios of 3 or 5 generally led to relatively small and inconsis-
tent improvements in correlation (Fig. 2; see also Table S3 in the
supplemental material). For hypoxanthine assays, where there was
concern that unreliable assays might be accepted with growth ra-
tios of 2 to 3 (see above), the mean proportion of additional iso-
lates excluded in this range ranged from 1.8 to 5.1% in the four
data sets (examining all drug pairs). The effects of various levels of
exclusion criteria in hypoxanthine assays (drug pairs MQ-QN and
CQ-DQ) are illustrated in Fig. S2 in the supplemental material.
IVART was therefore set to apply a default growth ratio of 2 to
classify the subset of curves with a fixed gamma. When this default
growth ratio was combined with the main criterion of a CIR of
3, 6,158 of 7,350 curves (83.8%) met the IVART core criteria.
Relative efficacies of artemisinins and partner drugs. Using
only data that conformed to the default IVART reliability criteria
(see above), it was possible to discern clear patterns in terms of the
growth ratio depending on the assay and the drug (Fig. 3). For
example, hypoxanthine-based assays showed the highest growth
ratios (typically 5- to 15-fold reductions in growth), while pro-
tein-based and SYBR green assays had substantially lower growth
ratios (i.e., relatively higher background values). Furthermore,
nonartemisinin drugs tended to show lower growth ratios than
artemisinin derivatives, an effect more marked with ELISA-based
assays.
This issue was explored in more detail by examining the pro-
portion of growth that could be inhibited {[G(C0)Gmin]/G(C0)}
(Fig. 1) by DHA compared to MQ for individual parasite isolates
for which both assays passed the core criteria. In all 11 data sets
with data for both drugs, MQ inhibited growth significantly less
than DHA (P, 0.01 by the Wilcoxon signed-rank test), but the
extent of this effect ranged from 1.0 to 30.2% (median values)
across data sets (Fig. 4). ELISA-based assays showed substantially
greater differences than those based on hypoxanthine incorpora-
tion or SYBR green fluorescence.
IVART online. The modeling approaches, constraints, and
core criteria described above were adopted within an online ver-
sion of IVART that is now available for external use at http://www
.wwarn.org/toolkit/data-management/ivart. After a one-time reg-
istration process, users have access to the tool via a personalized
interface that provides secure upload and storage of primary data
in a 96-well plate format. IVART incorporates a “Plate Assistant”
function to verify data layout and drug concentration information
and then undertakes a single-pass analysis that produces graphical
(Fig. 5) and spreadsheet reports for each individual assay, along
with summaries of reliable-assay subsets by drug and year of
study.
The range of drug concentrations in tests can also affect the
calculated IC50. In some data sets, the lowest concentration of the
drug tested demonstrated more than 50% inhibition, suggesting
Woodrow et al.
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that the drug concentration range tested was too high. Such assays
still provide useful information on drug sensitivity (as long as they
pass core criteria) but are marked in IVART with a “Range High”
warning, because reassessment of the range of concentrations
used in future assays may be indicated. Similarly, in some assays,
growth inhibition appears to be incomplete, even at the highest
drug concentration used. A “Range Low” warning is therefore
displayed when the level of inhibition at the highest concentration
of a drug is10% greater than that at the next lowest concentra-
tion. Cautious interpretation of such assay data is required, since
the effect may be explained by technical factors, such as underdos-
ing of the drug in the wells or hemolysis of red blood cells, but such
assays may also hint at emerging drug resistance.
DISCUSSION
A standardized approach to modeling in vitro data. Differences
in laboratory and analytical practices complicate the comparison
of data from antimalarial susceptibility assays obtained in differ-
ent laboratories. This problem can potentially be reduced in a
number of ways (2), including the use of validated reference
clones (25, 34, 35) and quality-controlled drugs (36). IVART was
developed to address a third source of variability by defining a
single approach to the calculation of IC50s that could be applied to
primary data collected using a range of growth readout methods.
Examination of a wide range of data sets from 11 in vitro testing
laboratories confirmed wide variations in experimental method
and design. The number and identity of drugs being assessed dif-
fers across laboratories, presumably influenced by local patterns
of clinical drug usage and susceptibility. This, in turn, affects the
number and range of drug concentrations assessed, along with the
number of no-drug control wells (critical for establishing a base-
line for calculating IC50s). In addition, some investigators select
specific subsets of control wells from certain rows or columns for
each drug, and control growth values may also be derived from
wells containing low drug concentrations if these produce higher
apparent growth than drug-free wells for any reason. Other po-
tential sources of variation include the use of different models for
curve fitting and manual removal of individual points considered
to be outliers.
We began the process of standardizing the calculation of IC50s
by selecting the sigmoid Emax nonlinear regression model for
curve fitting, since this does not involve subjective decisions re-
garding the form of the inhibition curve (a potential requirement
if a polynomial curve is used). The upper and lower bounds of the
model were constrained; given the range of plate layouts em-
ployed by different investigators, the upper constraint was defined
as the mean growth in all wells on the plate with no drug present.
Although edge and cross-plate changes in growth have been re-
ported (37), the use of this larger number of drug-free control
wells provides a statistical advantage in terms of greater numbers.
Several approaches to defining a lower constraint for curve
fitting of antimalarial susceptibility data have been described. In
hypoxanthine incorporation assays, the signal in uninfected red
blood cells can be used, while the background in ELISA-based
assays can be obtained by measuring the baseline antigen present
at the start of incubation. However, in practice, these parameters
are rarely recorded, and growth at the highest drug concentration,
G(Cmax), is commonly used; for example, G(Cmax) was the
method of choice in the original description of the LDH ELISA
(9). However, in the data sets examined here, the assumption that
the highest concentration of a drug defines its greatest level of
inhibition proved incorrect, since nearly one-fifth of assays
showed a paradoxical increase in apparent growth at very high
drug concentrations. This effect did not appear to be due simply to
FIG 2 Effects of differing reliability criteria on interdrug correlation. Each series of interconnected symbols represents the Pearson correlation coefficients for
chloroquine-desethylamodiaquine (CQ-DQ) (8 data sets) and mefloquine-quinine (MQ-QN) (11 data sets). Three levels of exclusion criteria were studied: a,
default IVART criteria; b, IVART criteria with additional exclusion of fixed-gamma assays with a growth ratio of 2 to 3; c, IVART criteria with additional exclusion
of fixed-gamma assays with a growth ratio of 3 to 5. Filled triangles, significant (P  0.05) correlation coefficients; open triangles, nonsignificant (P  0.05)
correlation coefficients. Individual correlation coefficients, P values, and numbers of samples are shown in Table S3 in the supplemental material.
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noise or outlying values, since it was more marked with nonarte-
misinin drugs and ELISA-based readouts. One possible explana-
tion for such paradoxical apparent growth at high drug concen-
trations is that drugs lacking a primary effect on the ring-stage
parasite at standard pharmacological concentrations may neverthe-
less affect the ring-stage parasite in other ways, leading to altered
transcriptional responses and increased protein production or nu-
cleic acid uptake. Additional explanations include precipitation of the
drug from the solution at high concentrations, plate edge effects (37),
and mixed-clone infections (38). Whatever the mechanism of this
higher apparent growth at high drug concentrations, the definition of
maximum growth inhibition clearly needs to account for cases where
maximum inhibition occurs at intermediate concentrations of a
drug. Ranking of concentrations in terms of the degree of inhibition
allowed the selection of a modified measure of maximal inhibition,
based on average growth over the two concentrations with the lowest
growth.
Systematic application of reliability criteria. Since a propor-
tion of parasites adapt poorly to in vitro culture and provide mis-
leading signals, investigators usually define a core subset of more-
reliable assays for use in association studies and summary outputs.
FIG 3 Growth ratios in nonmicroscopic forms of readout according to drug. Boxes show medians, while quartiles and whiskers indicate ranges. Dark shaded
boxes, artemisinin derivatives; light shaded boxes, ACT partner drugs; open boxes, chloroquine (CQ) and quinine (QN). Asterisks indicate significant reductions
in the growth ratio from that with DHA (P, 0.05 by the Mann-Whitney test with Bonferroni’s correction). Data sets are those listed in Table 1 and were obtained
by measurement of hypoxanthine incorporation (A to D), HRP2 (E to H), LDH (I to K), or SYBR green (L). Only assays passing core criteria were included.
FIG 4 Difference in proportional inhibition of growth {[G(C0)  Gmin]/
G(C0)} between dihydroartemisinin (DHA) and mefloquine (MQ) (as illus-
trated in Fig. 1). Medians and interquartile ranges are shown. Positive values
indicate greater efficacy of DHA than of MQ. Data sets (indicated along the y
axis) are those listed in Table 1 and were obtained by measurement of hypo-
xanthine incorporation (A to D), HRP2 (E to H), LDH (I to K), or SYBR green
(L). Only assays passing core criteria were included.
Woodrow et al.
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The method for defining such assays is rarely described in publi-
cations, and when conducted at the level of the individual assay,
the decision-making process is likely to be time-consuming and
potentially subjective. A key aim of IVART was to promote an
objective approach to be applied across whole data sets. IVART
uses a confidence interval ratio (CIR) of the IC50 estimate as its
main method of defining core assays: a CIR of3 is considered to
indicate a reliable assay. However, the CIR is not useful in a subset
of assays where initial 2-parameter modeling of the concentra-
tion-inhibition data fails and a fixed gamma value of 10 is used
(around 20% of all assays); in this scenario, other means of defin-
ing reliable assays are required. Measures of goodness of fit were
not chosen as IVART’s default criteria because of the clear evi-
dence that in a proportion of assays, the biological properties of
drug inhibition produce data that naturally deviate from the clas-
sical sigmoid concentration-inhibition curve (see above). Such
assays may be robust in terms of signal but nevertheless produce
poor scores in goodness-of-fit assessments and would tend to be
inappropriately rejected.
Historically, the overall level of signal to background (uninhib-
ited to maximally inhibited growth, known as the growth ratio)
has been recommended as a means of defining reliable curves (4).
Examination of the relationship between the growth ratio and the
confidence interval ratio across the data sets indicated that a
threshold growth ratio of 2 would lead to acceptance of very few
unreliable assays for ELISA- and SYBR green-based assays, and
this was adopted within the default criteria of IVART. However, it
was noted that there was a greater potential to accept less-reliable
data in hypoxanthine-based assays, where the signal-to-back-
ground ratio is usually much higher than 2. This is also consistent
with previous suggestions for reliability criteria in hypoxanthine-
based studies, for which a growth ratio of 5 was proposed (4). In
this study, when more-restrictive criteria were applied in hypox-
anthine-based data sets, leading to the exclusion of assays with
growth ratios of3 or5, relatively few additional isolates were
excluded (since such growth ratios are rarely encountered in hy-
poxanthine-based data sets, and the growth ratio is applied only to
the minority fixed-gamma subset). Accordingly, the correlation
FIG 5 Excerpt from an output PDF file showing results for a Ugandan sample tested with six drugs. IC50s are given in nanomolar concentrations. Growth values
for the zero-drug wells are plotted at the left-hand ends of the graphs (at 2 log units below the lowest drug concentration used) for display purposes.
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coefficients for MQ-QN and CQ-DQ did not, on the whole, im-
prove with these more-stringent criteria.
IVART was not designed with assays based on microscopic
assessment in mind, since the use of microscopy-based methods
to assess growth is decreasing. For all the drugs described here,
growth inhibition should be complete at high drug concentra-
tions, so the issues of determining maximal inhibition and the use
of the growth ratio (usually infinity in schizont maturation exper-
iments) to define reliable assays under certain circumstances do
not apply. Nevertheless, the tool may be useful to laboratories
continuing to use this methodology provided these issues are ap-
preciated.
Distinctive properties of artemisinin derivatives. The high-
throughput nature of IVART provided a unique opportunity to
undertake a systematic examination of growth characteristics
across a range of drugs and readout methods. As well as informing
the design of IVART itself, this process provided additional bio-
logical insights informative for the future design and interpreta-
tion of in vitro antimalarial susceptibility studies. There was clear
evidence that artemisinin derivatives show higher efficacy (i.e.,
inhibition of growth) than ACT partner drugs; for example, DHA
inhibited a significantly greater proportion of growth than MQ in
all sets of assays. This finding is consistent with the earlier onset of
action of artemisinins, at the ring stage of parasite development
(39–41), but the fact that this property is substantially greater in
ELISA-based readouts had not been documented previously. The
most likely reason for this is that both LDH and HRP2 are pro-
duced in significant quantities by ring-stage parasites (42), while
hypoxanthine and SYBR green signals accumulate only at more-
mature stages of asexual parasite development. There also ap-
peared to be an effect of site, possibly reflecting the critical role of
the timing of drug exposure in relation to the parasite stage. In
locations with substantial delays between the removal of the sam-
ple from the patient and the setup of in vitro culture, parasites are
more likely to first encounter the drug at mature stages, when they
are susceptible to a wider range of compounds.
These observations prompt a reevaluation of how resistance is
measured for different classes of antimalarial drugs. In the ACT
era, assessment may require different approaches for artemisinins,
which act rapidly against both the ring and mature stages, and
ACT partner drugs, which act only against the more-mature stages
of parasite development. The timing and duration of parasite-
drug contact have been identified as important determinants of
antimalarial susceptibility in the laboratory (2, 43), and specific
methodologies and analyses for different applications are likely to
provide more relevant information than a single method alone.
Both the microscopic and hypoxanthine methods were developed
in the era of slower-acting antimalarials with longer half-lives (CQ
and MQ) (44); in these assays, ring-stage parasites contribute little
signal (indeed, ring-stage growth is not assessed at all if hypoxan-
thine is added only after 24 h of incubation). In contrast, forms of
artemisinin resistance reported from Southeast Asia (27, 45, 46)
have been proposed to be confined to ring-stage parasites (47) and
would not be predicted to influence susceptibility at the tropho-
zoite or schizont stage. Short pulses of a drug during ring-stage
growth have lasting growth-inhibitory effects (39–41, 48–52), and
ring-stage pulse assays (in which relatively high concentrations of
artemisinins are applied for relatively short periods) have been
described recently (53, 54), providing the first clear view of ring-
stage artemisinin resistance in parasites from western Cambodia
(53). The need to remove a drug or to quantify ring-stage growth
using a specific marker may present a challenge for widespread
field use of this technique.
Summary and future work. IVART provides high-through-
put, rapid, single pass analysis of in vitro sensitivity data, avoiding
a variety of manual and potentially subjective processing steps
currently in use. The tool can be applied to data sets obtained by a
variety of methods and defines a subgroup of core IC50s of greater
reliability for pooled analyses and association studies. Its advan-
tages, therefore, relate to consistency of approach and conve-
nience.
The criteria suggested for accurate identification of a reliable
subset of assays for use in association studies appear to be well
suited to the signal-to-background properties of data sets from
ELISA and SYBR green assays (methods increasingly used by in
vitro testing laboratories); this is evidenced by substantially im-
proved correlation scores for interdrug comparisons upon the ap-
plication of these criteria. Nevertheless, ongoing monitoring of
the tool’s operation will be important in order to confirm pro-
spectively that the approaches described are appropriate for fur-
ther data sets from a variety of laboratories and methods. The
handling of assays with sparse data around the IC50, and conse-
quently steep falls in growth between two drug concentrations, is
a particular challenge for high-throughput approaches. Future in-
corporation of an additional algorithm that is better able to fit
2-parameter models to such data may provide a further advance,
although this will require careful validation on a similarly repre-
sentative data set. Large data sets of the type described here may
also be used to develop mixed-effects modeling approaches to the
analysis of concentration-inhibition data, involving a Bayesian
framework for assessing whether individual P. falciparum isolates
are resistant to a given drug.
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